Influenza Neuraminidase: A Neglected Protein and Its Potential for a Better Influenza Vaccine
Neuraminidase (NA) is an influenza surface protein that helps to free viruses from mucin-associated decoy receptors and to facilitate budding from infected cells. Experiments have demonstrated that anti-NA antibodies protect animals against lethal influenza challenge by numerous strains, while decre...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-07-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/8/3/409 |
| _version_ | 1797561499160412160 |
|---|---|
| author | Luca T. Giurgea David M. Morens Jeffery K. Taubenberger Matthew J. Memoli |
| author_facet | Luca T. Giurgea David M. Morens Jeffery K. Taubenberger Matthew J. Memoli |
| author_sort | Luca T. Giurgea |
| collection | DOAJ |
| description | Neuraminidase (NA) is an influenza surface protein that helps to free viruses from mucin-associated decoy receptors and to facilitate budding from infected cells. Experiments have demonstrated that anti-NA antibodies protect animals against lethal influenza challenge by numerous strains, while decreasing pulmonary viral titers, symptoms, and lung lesions. Studies in humans during the influenza A/H3N2 pandemic and in healthy volunteers challenged with influenza A/H1N1 showed that anti-NA immunity reduced symptoms, nasopharyngeal viral shedding, and infection rates. Despite the benefits of anti-NA immunity, current vaccines focus on immunity against hemagglutinin and are not standardized to NA content leading to limited and variable NA immunogenicity. Purified NA has been shown to be safe and immunogenic in humans. Supplementing current vaccines with NA may be a simple strategy to improve suboptimal effectiveness. Immunity against NA is likely to be an important component of future universal influenza vaccines. |
| first_indexed | 2024-03-10T18:15:46Z |
| format | Article |
| id | doaj.art-40dc8a15ece34a219a0431f443fdcff4 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-10T18:15:46Z |
| publishDate | 2020-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-40dc8a15ece34a219a0431f443fdcff42023-11-20T07:44:20ZengMDPI AGVaccines2076-393X2020-07-018340910.3390/vaccines8030409Influenza Neuraminidase: A Neglected Protein and Its Potential for a Better Influenza VaccineLuca T. Giurgea0David M. Morens1Jeffery K. Taubenberger2Matthew J. Memoli3LID Clinical Studies Unit, Laboratory of Infectious Diseases, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USANational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USAViral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USALID Clinical Studies Unit, Laboratory of Infectious Diseases, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USANeuraminidase (NA) is an influenza surface protein that helps to free viruses from mucin-associated decoy receptors and to facilitate budding from infected cells. Experiments have demonstrated that anti-NA antibodies protect animals against lethal influenza challenge by numerous strains, while decreasing pulmonary viral titers, symptoms, and lung lesions. Studies in humans during the influenza A/H3N2 pandemic and in healthy volunteers challenged with influenza A/H1N1 showed that anti-NA immunity reduced symptoms, nasopharyngeal viral shedding, and infection rates. Despite the benefits of anti-NA immunity, current vaccines focus on immunity against hemagglutinin and are not standardized to NA content leading to limited and variable NA immunogenicity. Purified NA has been shown to be safe and immunogenic in humans. Supplementing current vaccines with NA may be a simple strategy to improve suboptimal effectiveness. Immunity against NA is likely to be an important component of future universal influenza vaccines.https://www.mdpi.com/2076-393X/8/3/409influenzaneuraminidaseuniversal influenza vaccine |
| spellingShingle | Luca T. Giurgea David M. Morens Jeffery K. Taubenberger Matthew J. Memoli Influenza Neuraminidase: A Neglected Protein and Its Potential for a Better Influenza Vaccine Vaccines influenza neuraminidase universal influenza vaccine |
| title | Influenza Neuraminidase: A Neglected Protein and Its Potential for a Better Influenza Vaccine |
| title_full | Influenza Neuraminidase: A Neglected Protein and Its Potential for a Better Influenza Vaccine |
| title_fullStr | Influenza Neuraminidase: A Neglected Protein and Its Potential for a Better Influenza Vaccine |
| title_full_unstemmed | Influenza Neuraminidase: A Neglected Protein and Its Potential for a Better Influenza Vaccine |
| title_short | Influenza Neuraminidase: A Neglected Protein and Its Potential for a Better Influenza Vaccine |
| title_sort | influenza neuraminidase a neglected protein and its potential for a better influenza vaccine |
| topic | influenza neuraminidase universal influenza vaccine |
| url | https://www.mdpi.com/2076-393X/8/3/409 |
| work_keys_str_mv | AT lucatgiurgea influenzaneuraminidaseaneglectedproteinanditspotentialforabetterinfluenzavaccine AT davidmmorens influenzaneuraminidaseaneglectedproteinanditspotentialforabetterinfluenzavaccine AT jefferyktaubenberger influenzaneuraminidaseaneglectedproteinanditspotentialforabetterinfluenzavaccine AT matthewjmemoli influenzaneuraminidaseaneglectedproteinanditspotentialforabetterinfluenzavaccine |